Ybrain’s electroceutical for depression, MINDD STIM, surpasses 6,000 prescriptions


Ybrain, a company specializing in mental health diagnostics and therapeutics, said Wednesday that prescriptions for MINDD STIM, a prescription electroceutical for depression for home use, topped 6,000.

Ybrain’s MINDD STIM device for the treatment of depression via a home telemedicine platform exceeds 6,000 subscriptions.

MINDD STIMM is a wearable, wireless headband device that provides noninvasive brain stimulation through transcranial direct current stimulation, tDCS, to treat depression through frontal lobe normalization. Through this telemedicine platform, results are derived for the whole process, from scale mobile examination to hospital/home treatment, and patients can directly record and manage their symptoms.

This electroceutical prescription, which prevents the misuse/abuse of drugs and allows home treatment, was approved by the Ministry of Food Security and Medicine (MFDS) in April 2021.

This is the world’s first 100% home-based clinical trial with proven efficacy in improving symptoms of depression compared to other antidepressant medications, Ybrain said.

In June, MINDD STIM was selected by the Ministry of Health and Welfare for its innovative medical technology.

The device is not covered by health insurance but 46 local hospitals have prescribed MINDD STIM in 6,000 cases to date.

As a result, September saw the highest monthly utilization rate with 1,759 cases, and rose steadily after the announcement of non-reimbursement.

“MINDD STIM is confidently reaching patients in mental health clinics nationwide with a depression remission rate of 62.8% in accredited clinical trials,” said Ybrain CEO Lee Ki-won. “At the same time, we plan to continue expanding the blue band campaign launched in collaboration with the Korean Neuropsychiatric Association to create an atmosphere conducive to more active treatment of depression.”

CEO of Modu Psychiatric Clinic in Bundang, Dr Park Min-soo, who has been prescribing the device since June, said: “Women in their 50s who are reluctant to start drug treatment were hoping for a different treatment platform like this. that MINDD STIM provides. »

Park added, “Currently, patients are generally satisfied with MINDD STIM because there are no restrictions on activities and no discomfort during treatment, and the treatment effect for depression is also high as the number of treatments accumulates, so it is interesting for all age groups.”

At the same time, research is also underway to expand the indications for MINDD STIM. For example, a recent research article published in the international journal Stroke investigated the use of transcranial direct current stimulation (tDCS) to improve cognition in stroke patients using MINDD STIM. Ybrain. Therefore, the results showed that remotely supervised tDCS was a safe and feasible rehabilitation modality for post-stroke cognitive dysfunction.


About Author

Comments are closed.